Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the additive effect of brinzolamide
1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or
ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.